Affiliation:
1. 1University of California, San Francisco, California.
2. 2University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
Abstract
SummaryA recent phase Ib/II trial evaluated the combination of tucatinib, letrozole, and palbociclib in patients with HR+/HER2+ metastatic breast cancer, demonstrating a manageable safety profile and encouraging efficacy data. An all-oral, chemotherapy-free regimen is an appealing strategy, and could be a possible maintenance or primary therapy option in select patients.See related article by Shagisultanova et al., p. 5021
Publisher
American Association for Cancer Research (AACR)
Reference13 articles.
1. Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer;Shagisultanova;Clin Cancer Res,2023
2. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer;Swain;N Engl J Med,2015
3. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer;Cortés;N Engl J Med,2022
4. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer;Murthy;N Engl J Med,2020
5. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial;Krop;Lancet Oncol,2017